Home › NDC Lookup › Ingredients › Triamcinolone Acetonide › 00316-0165-15
TRIDERM Triamcinolone Acetonide .25 mg/g Cream — NDC 00316-0165-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

TRIDERM Triamcinolone Acetonide .25 mg/g Cream — NDC 0316-0165-15 (Billing 00316-0165-15)

by Crown Laboratories · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of TRIDERM Triamcinolone Acetonide .25 mg/g Cream from Crown Laboratories, marketed since Mar 1984 and currently FDA-listed. It is the main listing for this product, which comes in 3 package sizes.

NDC 00316-0165-15
🏷️ FDA NDC (as labeled) 0316-0165-15 billing pads the labeler segment with a zero
This package
Contains15 g in 1 tube Pack sizes3 compare ↓
Also priced by: Part D plans $0.3231/unit — full pricing hub ↓
Main listing for product 0316-0165 · Also comes in: 454 g 0316-0165-16 85.2 g 0316-0165-85
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Sep 28, 2023 — Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial. (Eugia US LLC) · FDA recall D-0041-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0316-0165-15
Product NDC 0316-0165
11-digit billing NDC 00316016515
RxCUI 1014314, 1085644, 1085686, 1085773, 1648997, 1648999
UNII F446C597KA
UPC 0303160175152, 0303160165153, 0303160170010
Application # ANDA088042
SPL Set ID 2c7fee2c-6f57-4de4-8803-98c0b31b07c3
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1984-03-19
Route TOPICAL
Dosage form CREAM
Substance TRIAMCINOLONE ACETONIDE
TE code (Orange Book) AT · RLD · RS
Quick answers
  • RxCUI (RxNorm): 1014314
Why two NDCs? The FDA registers this code as 0316-0165-15 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00316-0165-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📖 What it is MedlinePlus · NLM

Triamcinolone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). It is also used as a dental paste to relieve the discomfort of mouth sores. Triamcinolone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Injections treat severe allergic conditions, joint inflammation, certain skin problems and eye inflammation. Creams and ointments calm itchy, inflamed sk...
  • Injections are given by a healthcare professional. Ointment is applied as a thin film to the affected area two to three times daily. Nasal spray bottles need priming before first u...
  • Possible effects include injection site pain, joint swelling, headache, muscle spasms, cough, sinusitis and bruising. People with diabetes may see higher blood sugar. Tell your doc...
  • Call right away for signs of an allergic reaction, fever or infection, a very painful and swollen joint, vision changes, or mood changes. Also report black stools, severe stomach p...
📖 Read our full Triamcinolone guide →
8
Nutrient depletion considerations

Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Triamcinolone Acetonide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.3231 $4.85 / 15 g
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00316-0165-15 You're viewing this Main listing 1 TUBE in 1 CARTON / 15 g in 1 TUBE 2015-03-25 — Active
00316-0165-16 0316-0165-16 1 JAR in 1 CARTON / 454 g in 1 JAR 2015-03-25 — Active
00316-0165-85 0316-0165-85 1 TUBE in 1 CARTON / 85.2 g in 1 TUBE 2015-03-25 — Active

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 15 g in 1 tube.
What NDC number is used to bill for this package of TRIDERM Triamcinolone Acetonide .25 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Triamcinolone Acetonide .25 mg/g 45802-0063-05 Padagis 454 g $0.035 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 45802-0054-05 Padagis 454 g $0.047 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 00168-0005-80 E. 80 g $0.074 AT Availability likely —
triamcinolone acetonide .25 mg/g 00168-0003-15 E. 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 00713-0226-15 Cosette 1 tube $0.120 AT Discontinued —
Triamcinolone Acetonide .25 mg/g 16714-0985-01 NorthStar 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 33342-0327-15 Macleods 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 67877-0317-15 Ascend 15 g $0.120 AT Availability likely —
Triamcinolone acetonide .25 mg/g 33342-0331-15 Macleods 1 tube $0.239 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 00713-0229-15 Cosette 1 tube $0.239 AT Availability likely —
Triamcinolone acetonide .25 mg/g 16714-0267-01 NorthStar 1 tube $0.239 AT Availability likely —
Triderm .25 mg/gthis 00316-0165-15 Crown 1 tube — AT FDA listed —
triamcinolone acetonide .25 mg/g 50090-0293-01 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-2658-00 A-S 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-3704-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63187-0214-80 Proficient 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8782-01 Bryant 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8784-01 Bryant 454 g — AT FDA listed —
Triamcinolone acetonide .25 mg/g 68071-2361-01 NuCare 15 g — AT FDA listed —
triamcinolone acetonide .25 mg/g 68788-8515-08 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 68788-8899-01 Preferred 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 71335-2870-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-1835-02 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-2334-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 76420-0347-15 Asclemed 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 76420-0360-80 Asclemed 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8841-01 Bryant 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-2335-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-3802-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 68788-4148-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-0362-00 A-S 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1984
On the market since
Mar 1984
📍
2026
Currently FDA-listed
42 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 5ZA2S6B08X
    Cetyl palmitate is a waxy substance made from natural fats. It works as a binder and thickener to help hold the medicine together and control how it dissolves in your body.
  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII Q504PL8E0V
    A waxy emulsifier blend derived from sorbitan and polyethylene glycol. It helps mix oil and water-based ingredients together and is commonly used in creams and ointments to create a smooth, uniform texture.
  • UNII 1VPU26JZZ4
    Potassium sorbate is a salt derived from sorbic acid, a naturally occurring preservative. It prevents growth of mold, yeast, and some bacteria, extending the medicine's shelf life.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII X045WJ989B
    Sorbic acid is a preservative derived from berries that prevents mold, yeast, and bacterial growth in medicines. It keeps the product stable and safe during storage.
  • UNII 506T60A25R
    Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

8 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCrown Laboratories
Application holderCROWN LABORATORIES INC
FDA applicationANDA088042 (ANDA)
Labeler code00316
First marketedMar 1984
Product typeHuman Prescription Drug
Portfolio43 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 19 words ▾

INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

⏱️ Dosage and Administration 71 words ▾

DOSAGE AND ADMINISTRATION Apply to the affected area as a thin film from two to four times daily for the 0.025% strength and two or three times daily for the 0.1% and 0.5% strength depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 59 words ▾

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.

🤰 Pregnancy 92 words ▾

Pregnancy Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.

Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 118 words ▾

Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenaI (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.

🆘 Overdosage 17 words ▾

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS )

🧬 Clinical Pharmacology 192 words ▾

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.

Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.

(See DOSAGE AND ADMINISTRATION ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees.

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📦 How Supplied / Storage and Handling 64 words ▾

HOW SUPPLIED Triderm (Triamcinolone Acetonide Cream USP), 0.025% is supplied in: 15 grams tube NDC 0316-0165-15 85.2 grams tube NDC 0316-0165-85 454 grams jar NDC 0316-0165-16 Triderm (Triamcinolone Acetonide Cream USP), 0.1% is supplied in: 28.4 grams tube NDC 0316-0170-01 85.2 grams tube NDC 0316-0170-03 Triderm (Triamcinolone Acetonide Cream USP), 0.5% is supplied in: 15 grams tube NDC 0316-0175-15 454 grams jar NDC 0316-0175-16

📦 Storage and Handling 22 words ▾

STORAGE Store at room temperature 20 o - 25 o C (68 o - 77 o F) [see USP Controlled Room Temperature]

📋 Description 166 words ▾

DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Triamcinolone acetonide is chemically pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-(11β, 16α)- with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50.

Its structural formula is: Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.025% contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.1% contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.5% contains 5 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. TA structure

💬 Information for Patients 127 words ▾

Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only.

Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.

3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. 4.

Patients should report any signs of local adverse reactions especially under occlusive dressing. 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

🍼 Nursing Mothers 58 words ▾

Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 38 words ▾

Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

📄 Package Label / Principal Display Panel ~3 min read ▾

Triderm (Triamcinolone Acetonide Cream USP), 0.1% tube label NDC 0316-0170-01 Rx Only TRIDERM TM Triamcinolone Acetonide Cream USP, 0.1% 1 oz (28.4 grams) WARNING: Keep Out Of Reach Of Children. For external use only. Not for ophthalmic use. .

Each gram contains: 1 mg Triamcinolone Acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Usual Dosage: 2 to 3 applications daily. See package insert for full prescribing information.

TO OPEN: Use cap to puncture seal. IMPORTANT: Do not use if seal has been punctured or is not visible. Store at 20 o -25 o C (68 o -77 o F) [see USP Controlled Room Temperature].

Avoid excessive heat. Protect from freezing. See Crimp of tube for Expiration Date and Batch Number.

Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, TN 37604 0.1% Label

Triderm (Triamcinolone Acetonide Cream USP), 0.1% carton label NDC 0316-0170-01 Rx Only TRIDERM TM Triamcinolone Acetonide Cream USP, 0.1% 1 oz (28.4 grams) WARNING: Keep Out Of Reach Of Children. For External Use Only. Not for Ophthalmic Use.

Each gram contains: 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Directions for puncturing tube seal: Remove cap. Turn cap upside down and place puncture tip onto tube seal: push down until seal is punctured.

Screw cap back on to close. IMPORTANT: Do not use if seal has been punctured or is not visible. Store at 20 o -25 o C (68 o -77 o F) [see USP Controlled Room Temperature].

Avoid excessive heat. Protect from freezing. Manufactured and Distributed by: Crown Laboratories, Inc.

Johnson City, TN 37604 Usual Dosage: 2 to 3 applications daily. See package insert for full prescribing information. See end of carton for batch number and expiration date.

0.1% Carton

Triderm (Triamcinolone Acetonide Cream USP), 0.025% tube label NDC 0316-0165-15 Rx Only TRIDERM CREAM TM Triamcinolone Acetonide Cream USP, 0.025% 15 grams WARNING: Keep out of reach of children For External Use Only Not for Ophthalmic Use Store at 20 o -25 o C (68 o -77 o F) [see USP Controlled Room Temperature] Avoid excessive heat. Protect from freezing. Each gram contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.

USUAL DOSAGE: 2 or 4 applications daily. See package insert for full prescribing information. TO OPEN: Use cap to puncture seal.

IMPORTANT: Do not use if seal has been punctured or is not visible. See crimp of tube for batch number and expiration date. Manufactured and Distributed by: Crown Laboratories, Inc.

Johnson City, TN 37604 0.025% Label

Triderm (Triamcinolone Acetonide Cream USP), 0.025% carton label NDC 0316-0165-15 Rx Only TRIDERM CREAM TM Triamcinolone Acetonide Cream USP, 0.025% 15 grams WARNING: Keep out of reach of children For External Use Only Not for Ophthalmic Use USUAL DOSAGE: 2 or 4 applications daily. See package insert for full prescribing information. See end of carton for batch number and expiration date.

Each gram contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Directions for puncturing seal: Remove cap. Turn cap upside down and place puncture tip onto tube seal; push down until seal is punctured.

Screw cap back on to close IMPORTANT: Do not use if seal has been punctured or is not visible. Store at 20 o -25 o C (68 o -77 o F) [see USP Controlled Room Temperature] Avoid excessive heat. Protect from freezing.

Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, TN 37604 0.025% Carton

Triderm… [Excerpted — this section continues on DailyMed.]

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Triamcinolone Acetonide (matched by generic name) — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Triamcinolone Acetonide. CMS lists 5 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$17.79M
Claims incl. refills
1.7M
Beneficiaries
1.4M
Spend / beneficiary
$13.01
Spend / claim
$10.45
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Crown Laboratories. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 1 jar (00316-0165-16), 1 tube (00316-0165-85). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Crown Laboratories is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00316-0143-15 · CROWN 00316-0170-01 · Crown →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.